Matches in DBpedia 2014 for { ?s ?p Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.Beginning in 2007, it underwent Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment were also undertaken.On February 27, 2008, AstraZeneca announced that the use of Cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.On 8 March 2010, AstraZeneca issued a press-release stating that Cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader bevacizumab.As of November 2012, it was being assessed in double-blind studies for the treatment of methylated Glioblastoma Multiforme at the University of Washington Medical Center at a 20 mg daily dose.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Cediranib abstract "Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.Beginning in 2007, it underwent Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment were also undertaken.On February 27, 2008, AstraZeneca announced that the use of Cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.On 8 March 2010, AstraZeneca issued a press-release stating that Cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader bevacizumab.As of November 2012, it was being assessed in double-blind studies for the treatment of methylated Glioblastoma Multiforme at the University of Washington Medical Center at a 20 mg daily dose.".